Sequana Medical

94 articles about Sequana Medical

• Strong data from DSR® proof-of-concept studies in heart failure published in European Journal of Heart Failure

  4/3/2024

  Sequana Medical NV announces that the results from two proof-of-concept studies, RED DESERT and SAHARA, of the Company’s DSR therapy in patients with diuretic-resistant heart failure have been published in the prestigious peer-reviewed journal European Journal of Heart Failurei.

• Sequana Medical announces 2023 Full Year Results and 2024 Outlook

  3/28/2024

  Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces its financial results for the year ended 31 December 2023, and provides a business update and outlook for 2024 and beyond.

• Strong data from DSR® proof-of-concept studies in heart failure accepted for late-breaking presentation at THT 2024

  2/28/2024

  Sequana Medical NV announces that the late-breaking abstract including data from the RED DESERT and SAHARA proof-of-concept studies of the Company’s DSR therapy in patients with diuretic-resistant heart failure have been selected for a late-breaking presentation at THT 2024.

• Transparency Notifications from Shareholders - Jan 24, 2024

  1/24/2024

  Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces that it received transparency notifications from the shareholders listed below, notifying the number of voting rights attached to shares mentioned next to their respective names in the table below.

• Sequana Medical announces DSMB approval to start randomized MOJAVE cohort – US Phase 1/2a study of DSR® 2.0 for treatment of heart failure

  1/23/2024

  Sequana Medical NV announces that an independent Data and Safety Monitoring Board approved the start of the randomized cohort in MOJAVE, the US Phase 1/2a study of DSR 2.0 for treatment of patients with diuretic-resistant heart failure, following review of the safety data reported from the non-randomized cohort.

• Transparency Notifications from Shareholders - Jan 15, 2024

  1/15/2024

  Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces that it received a transparency notification from the shareholders listed below, notifying the number of voting rights attached to shares mentioned next to their respective names in the table below.

• Sequana Medical granted US CPT® III reimbursement codes for alfapump® system

  1/3/2024

  Sequana Medical NV announces that the American Medical Association has issued six new Category III Current Procedural Terminology codes for the alfapump system, an important step in facilitating reimbursement for the Company’s innovative medical device for the treatment of recurrent or refractory ascites due to liver cirrhosis.

• Sequana Medical submits Premarket Approval application to US FDA for alfapump® in recurrent or refractory ascites due to liver cirrhosis

  12/28/2023

  Sequana Medical NV announces that it has submitted a Premarket Approval application to the US Food and Drug Administration for alfapump, the Company’s fully implantable, wirelessly charged device for patients with recurrent or refractory ascites due to liver cirrhosis.

• Sequana Medical announces positive data from non-randomized cohort in US Phase 1/2a MOJAVE study of DSR® 2.0 for treatment of heart failure

  11/29/2023

  Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces that all three patients from the non-randomized cohort of the MOJAVE study were successfully treated with DSR 2.0.

• Sequana Medical announces results of Extraordinary General Meeting of Shareholders - November 10, 2023

  11/10/2023

  Sequana Medical NV announces that all proposed resolutions submitted to the Extraordinary General Meeting of Shareholders were approved at the meeting held today at 09:00 am CET.

• Sequana Medical announces additional alfapump data supporting strong and durable clinical profile; PMA on track for year-end submission

  10/19/2023

  Conference call with live webcast by Sequana Medical today at 03:00 pm CEST / 09:00 am EST

• Sequana Medical announces initial positive data from MOJAVE, a US Phase 1/2a study of DSR® 2.0 for treatment of heart failure through breaking vicious cycle of cardiorenal syndrome

  10/18/2023

  Sequana Medical NV announces that the first two patients from the non-randomized cohort of the MOJAVE study were successfully treated with DSR 2.0, including safe and effective maintenance of euvolemia without the need for loop diuretics, considerable benefit in their cardiorenal status and a dramatic improvement in their diuretic response and loop diuretic requirements.

• Sequana Medical announces H1 2023 results and provides business update

  9/14/2023

  Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces its business highlights and financial results for the six-month period ending 30 June 2023 and its outlook for the remainder of the year.

• Sequana Medical Notice of 2023 Half-year Results and Business Update

  9/6/2023

  Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, will announce its half-year results ended 30 June 2023 on Thursday, 14 September 2023.

• 1,000th alfapump® implant completed

  7/6/2023

  Sequana Medical NV announces that it has implanted the 1,000thalfapump for the treatment of recurrent and refractory ascites due to liver cirrhosis and malignant ascites.

• Sequana Medical announces results of Special General Meeting of Shareholders

  6/26/2023

  Sequana Medical NV announces that all proposed resolutions submitted to the Special General Meeting of Shareholders were approved at the meeting held today at 09:00 am CEST.

• Additional data from North American pivotal alfapump® study (POSEIDON) will be presented at EASL Congress 2023

  6/19/2023

  Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical") today announces that data from POSEIDON, its North American pivotal study of the alfapump will be presented during two poster sessions at the EASL Congress 2023, taking place in Vienna, Austria from 21 to 24 June 2023.

• Sequana Medical announces results of Annual General Meeting of Shareholders

  5/25/2023

  Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces that all proposed resolutions submitted to the Annual General Meeting of Shareholders were approved at the meeting held today at 09:00 am CEST.

• Sequana Medical announces FDA clearance of IND application for DSR® 2.0 for treatment of congestive heart failure

  5/2/2023

  Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces that the US Food and Drug Administration has cleared its Investigational New Drug application for its second-generation DSR product for the treatment of congestive heart failure.

• Sequana Medical announces additional patents for DSR® in China and the United States

  3/22/2023

  Sequana Medical NV announces further strengthening of the intellectual property portfolio for its DSR program.